These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 4050651)

  • 21. [Treatment of recurrent ventricular tachycardias using oral propafenone].
    Cointe R; Lévy S; Metge M; Vrancea F; Labrunie P; Valeix B; Gérard R
    Arch Mal Coeur Vaiss; 1985 Oct; 78 Spec No():59-62. PubMed ID: 3938260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexes.
    Salerno DM; Granrud G; Sharkey P; Asinger R; Hodges M
    Am J Cardiol; 1984 Jan; 53(1):77-83. PubMed ID: 6362387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia.
    Shen EN; Sung RJ; Morady F; Schwartz AB; Scheinman MM; DiCarlo L; Shapiro W
    J Am Coll Cardiol; 1984 May; 3(5):1291-7. PubMed ID: 6707382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced survival in patients with heart failure and life-threatening ventricular tachyarrhythmias.
    Brodsky MA; Allen BJ; Baron D; Chesnie BM; Abate D; Thomas R; Henry WL
    Am Heart J; 1986 Dec; 112(6):1166-72. PubMed ID: 3788763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapy of ventricular tachyarrhythmias refractory to lidocaine with propafenone (author's transl)].
    Laimer H; Glogar D; Zilcher H
    Acta Med Austriaca; 1981; 8(5):140-4. PubMed ID: 7331741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of associated propafenone in patients with amiodarone-resistant ventricular tachycardia.
    Morgera T; Dreas L; Humar F; Maras P; Chersevani D; Camerini F
    Int J Cardiol; 1991 May; 31(2):187-97. PubMed ID: 1869328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relation of acute antiarrhythmic drug efficacy to left ventricular function in coronary artery disease.
    Meissner MD; Kay HR; Horowitz LN; Spielman SR; Greenspan AM; Kutalek SP
    Am J Cardiol; 1988 May; 61(13):1050-5. PubMed ID: 3284319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of antiarrhythmic drug efficacy in patients with malignant ventricular tachyarrhythmias.
    Hohnloser SH; Raeder EA; Podrid PJ; Graboys TB; Lown B
    Am Heart J; 1987 Jul; 114(1 Pt 1):1-7. PubMed ID: 3604854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind placebo-controlled evaluation of propafenone in suppressing ventricular ectopic activity.
    Hodges M; Salerno D; Granrud G
    Am J Cardiol; 1984 Nov; 54(9):45D-50D. PubMed ID: 6388303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognosis of patients with ventricular tachycardia or fibrillation and a normal electrophysiologic study.
    Kim SG; Aboaf AP; Roth J; Ferrick K; Fisher JD
    Am Heart J; 1991 Jan; 121(1 Pt 1):77-80. PubMed ID: 1985381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of propafenone in patients with stable ventricular arrhythmias.
    de Soyza N; Terry L; Murphy ML; Thompson CH; Doherty JE; Sakhaii M; Dinh H
    Am Heart J; 1984 Aug; 108(2):285-9. PubMed ID: 6380253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reappraisal of criteria for assessing drug efficacy in patients with ventricular tachyarrhythmias: complete versus partial suppression of inducible arrhythmias.
    Borggrefe M; Trampisch HJ; Breithardt G
    J Am Coll Cardiol; 1988 Jul; 12(1):140-9. PubMed ID: 3379199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arrhythmogenic effects of antiarrhythmic drugs: a study of 506 patients treated for ventricular tachycardia or fibrillation.
    Stanton MS; Prystowsky EN; Fineberg NS; Miles WM; Zipes DP; Heger JJ
    J Am Coll Cardiol; 1989 Jul; 14(1):209-15; discussion 216-7. PubMed ID: 2738263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Propafenone in ventricular hyperkinetic arrhythmias. Dynamic ECG evaluation of the acute oral test and short-term treatment].
    Garimoldi M; Sghirinzetti M; Pirastu A; Cappiello E; Sala R; Terranova P
    G Ital Cardiol; 1986 Apr; 16(4):328-32. PubMed ID: 2427383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up.
    Breithardt G; Borggrefe M; Wiebringhaus E; Seipel L
    Am J Cardiol; 1984 Nov; 54(9):29D-39D. PubMed ID: 6496367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive evaluation of indecainide for serious ventricular tachyarrhythmia.
    Podrid PJ; Hohnloser S; Lown B
    Am J Cardiol; 1988 Apr; 61(10):764-9. PubMed ID: 2451415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of propafenone on left ventricular ejection fraction.
    Baker BJ; Dinh H; Kroskey D; de Soyza ND; Murphy ML; Franciosa JA
    Am J Cardiol; 1984 Nov; 54(9):20D-22D. PubMed ID: 6496365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Propafenone for the treatment of severe ventricular arrhythmias.
    Rabkin SW; Rotem CE; Boroomand-Rashti K; Bar-Shlomo B
    Can Med Assoc J; 1984 Sep; 131(6):601-3. PubMed ID: 6478345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Idiopathic ventricular tachyarrhythmia. Spontaneous variability and effect of various antiarrhythmic agents].
    Korsukewitz J; Wegscheider K; Schmutzler H
    Dtsch Med Wochenschr; 1985 Jul; 110(28-29):1103-7. PubMed ID: 2408842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.